Loading...
Market
Will Roche announce a new cancer treatment using Poseida's tech by mid-2026?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Roche's official press releases or announcements at medical conferences
Story
Roche Completes $1.5 Billion Acquisition of Poseida Therapeutics, Securing 66% Stake by January 8
Jan 8, 2025, 12:15 PM
Roche Holdings AG has successfully completed its tender offer for Poseida Therapeutics, Inc., acquiring a 66% stake in the U.S. genetic engineering firm. The transaction, valued at approximately $1.5 billion, aims to enhance Roche's capabilities in developing new cancer treatments. The acquisition is set to finalize on January 8, 2025, following the completion of the tender offer, which saw significant participation from shareholders.
View original story
Similar markets
Novartis • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Roche • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
